Novo Nordisk A/S is trading 4.3% up today at $43.99 as investors provide a more constructive reassessment of recent obesity drug trial data.
- The stock is rebounding from an initial slide on June 9, 2026, following a shift in sentiment regarding Phase 2 amycretin results which showed 14.6% weight loss.
- Analysts suggest the move reflects growing confidence in the company's long-term pipeline potential despite a weak broader market.